Abstract
Four healthy subjects volunteered for a crossover bioavailability study to compare the rate and extent of absorption of plain capsules and new slow-release capsules of ketoprofen.
The formulations were administered in two consecutive 4-day periods at the following dose schedules: 2 × 50 mg plain capsules t.i.d. and 150 mg slow-release capsules b.i.d.
The plasma levels profile of unchanged ketoprofen was assessed by GLC during the 4th day of treatment with each formulation.
The absorption from slow-release capsules was slower and more sustained than from plain capsules but almost complete.
The bioavailability properties of new slow-release capsules of ketoprofen appear suitable for clinical use with reduced frequency of daily dosing.
Get full access to this article
View all access options for this article.